Juvena Therapeutics | $33,500,000 | (Jan 14, 2026)
Allos | $5,000,000 | (Jan 14, 2026)
Nodu | $1,450,000 | (Jan 14, 2026)
ReCode Therapeutics
United States
- Menlo Park, California & Dallas, Texas
- 20/09/2023
- Series B
- $50,000,000
ReCode Therapeutics is a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver.
- Industry Biotechnology Research
- Website https://recodetx.com/
- LinkedIn https://www.linkedin.com/company/recode-therapeutics/about/
Related People
Shehnaaz SulimanFounder
United States -
San Mateo, California
- 25+ years in transforming and building Biotech Companies
- Business Development, Corporate & Commercial Strategy, Early Development, Portfolio Management, FInancing and Capital raising (Gilead, Genentech, Roche, Theravance, Alector, ReCode)
- Licensing and M&A transactions exceeding $15B
- >20M patients on treatment through developing world access partnerships
- Early and late development pipeline progress - IND to Ph3
- Independent Director: Ultragenyx Pharmaceuticals (RARE), 10x Genomics (TXG)
- Forbes 50 over 50 Leader (2023), Silicon Valley Business Journal Top 100 Women of Influence Leader (2023) Power 50 Leader (2021) and Fiercest Women in Life Science (2017),
- ReCode Named a Fierce 15 winner (2022)
Cytotheryx, Inc. | $60,000,000 | (Jan 13, 2026)
MEDIPOST, Inc. | $140,000,000 | (Jan 13, 2026)
TRYBE | $30,000,000 | (Jan 13, 2026)
Diagonal Therapeutics | $125,000,000 | (Jan 13, 2026)
VelaFi | $20,000,000 | (Jan 13, 2026)
encoord | $2,000,000 | (Jan 13, 2026)
Avenue Biosciences | $7,500,000 | (Jan 13, 2026)
Unusual | $3,600,000 | (Jan 13, 2026)
BlueNalu | $11,000,000 | (Jan 13, 2026)